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The treatment of Benign Prostatic Hyperplasia (BPH) has been 
recently approved by different international guidelines like AUA, 
EAU, NICE, WHO consultation, etc, and drugs as the alpha-blockers 
and the 5-alpha-reductase inhibitors are widely indicated for this 
disease [1].
Moreover, little space is given to the anti-cholinergics and recently 
to the phosphodiesterase type 5 inhibitors. 
In this field of application, the phytotherapics, in particular 
Serenoa repens, are less or not recommended, because they are not 
supported by adequate scientific evidence.
However, the use of these molecules is widely diffuse all over the 
world, achieving the first choice of treatment in some Nations such as 
the Asians.
One needs only to consider that in the United States the business 
of the dietary supplements/phytotherapics has exceeded that of the 
pharmaceutical industry. In Europe it has been spent over 5.7 billion 
euros for these products and in Italy the business has grown from 
2003 until now by more than 70% with a turnover of 1500 million 
euros in the 2009. In detail, the business of Serenoa repens is about 15 
million euros for the treatment of BPH [2-3].
However we are starting to wonder. Why this wide diffusion of 
these products? What often makes them preferable to conventional 
drugs? Why the lack of scientific evidence is not enough to limit their 
use? It is not easy to answer these questions. At first, we think that 
these molecules possess either an empirical efficacy or an absolute 
tolerability. The side effects of  Serenoa repens are truly equivalent to 0%. 
In particular it does not determine side effects on the cardiovascular 
system nor on the gastrointestinal and in details it does not injure any 
aspect of male sexuality like impotence or ejaculatory disorders.
In our opinion, a second point of view consists on the specificity 
of the treatment. We all know how it does not exist a definitive and 
curative possibility to cure BPH. The use of alpha-blockers or 5-alpha-
reductase inhibitors is only related with an improvement of the 
micturition symptoms or with a reduction of the prostate volume that 
does not mean resolution of the disease.
The association between the “lack of efficacy” and the “lack 
of side effects” has probably contributed to the diffusion of these 
molecules although they do not determine a symptomatic relief. In 
fact, phytotherapics are preferred by physicians and patients, who are 
influenced by the absence of definitive treatment, thanks to the better 
tolerability profile of these molecules.
Then, we may affirm that the diffusion of Phytotherapy is due to 
the absence of essential alternatives. 
We must not forget the lack of adherence of physicians and 
urologists to the international guidelines. In particular it is obvious 
to use all available diagnostic information to compose an as exact as 
possible algorithm for treatment (i.e. IPSS symptom score, micturition 
diaries, multiple flow measurements, PSA determination, sexual 
examination and erectile function evaluation) [4]. Doing so, the 
urologist will be able to identify the patients who may receive medical 
treatment and even Phytotherapy or combination.
All these considerations are also connected to the poor knowledge 
and information about the treatment of BPH. Which will be the 
future?
We think that scientific evidences about phytotherapics should 
be demonstrated and well conducted clinical studies are needed to 
clarify the efficacy of these molecules on BPH. Furthermore, it should 
be intensified the knowledge about the mechanisms of action of these 
phytotherapics, not only in vitro but also in animals and in humans 
[5-6].
Last but not least it should be better regulated the wide use of 
different phytotherapics because, being them extractive products 
and not synthetic products, they may elicit a great variability within 
molecules and different therapeutic results between many compounds.
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